RhG-CSF Injection(Filgrastim) (Recombinant Human Granulocyte Colony-Stimulating Factor) – A Drug To Increase White Blood Cell Count, CAS No.: 121181-53-1

Introduction:

As a manufacturer in China, we are proud to introduce our product RhG-CSF Injection (Filgrastim), a recombinant human granulocyte colony-stimulating factor that is designed to increase white blood cell count. Our product is vital for individuals who are suffering from diseases that affect the production of white blood cells, such as cancer and infectious diseases.

Our RhG-CSF Injection is made using the latest technology and is manufactured according to international standards. The product has been clinically tested and has shown excellent results in increasing white blood cell count in patients. We are confident that our product will be the perfect addition to any medical facility or hospital and offer a solution to those in need.

Benefits of RhG-CSF Injection:

Our RhG-CSF Injection has several benefits that make it an ideal product for merchants looking to purchase high-quality medical products for their customers. Some of the notable benefits include:

1. Increase in white blood cell count: Our product is designed to stimulate the production of white blood cells in the body, helping to fight off infections and diseases.

2. Improved immune system: The increase in white blood cell count helps to strengthen the immune system, making it easier for patients to fight off infections.

3. Reduced risk of infection: Patients who are suffering from conditions that affect white blood cell production are at a higher risk of developing infections. Our product reduces this risk, making it an essential tool in the battle against infectious diseases.

4. Safe and reliable: Our RhG-CSF Injection is made using high-quality ingredients and is manufactured to international standards. This ensures that the product is safe and reliable, giving merchants and customers peace of mind.

Applications of RhG-CSF Injection:

Our RhG-CSF Injection has several applications in the medical field, making it a versatile and valuable product for merchants to offer their customers. Some of these applications include:

1. Cancer treatment: Patients undergoing chemotherapy and radiation therapy often experience a decrease in white blood cell count, leaving them vulnerable to infections. Our RhG-CSF Injection can help to maintain their white blood cell count during treatment, reducing the risk of infection.

2. Bone marrow transplant: Patients who undergo bone marrow transplants often require an increase in white blood cell count to prevent infections. Our RhG-CSF Injection can help to stimulate white blood cell production in these patients, reducing the risk of infection.

3. Chronic neutropenia: Patients who suffer from chronic neutropenia have a decreased white blood cell count, leading to an increased risk of infections. Our RhG-CSF Injection can help to stimulate white blood cell production, reducing the risk of infection in these patients.

Conclusion:

In conclusion, our RhG-CSF Injection (Filgrastim) is a safe, reliable, and effective solution for patients suffering from conditions that affect white blood cell production. The benefits of our product make it an appealing choice for merchants looking to offer their customers high-quality medical products that are in high demand.

We are confident that our RhG-CSF Injection will become an essential tool in the battle against infectious diseases, and we look forward to working with merchants worldwide to provide this valuable product to those in need.

DESCRIPTION

Filgrastim is a 175 amino acid human granulocyte colony-stimulating factor (G-CSF) manufactured by recombinant DNA technology. Filgrastim is produced by Escherichia coli (E coli) bacteria into which has been inserted the human granulocyte colony-stimulating factor gene. Filgrastim has a molecular weight of 18‚800 daltons. The protein has an amino acid sequence that is identical to the natural sequence predicted from human DNA sequence analysis‚ except for the addition of an N-terminal methionine necessary for expression in E coli. Because filgrastim is produced in E coli‚ the product is non-glycosylated and thus differs from G-CSF isolated from a human cell.

FILGRASTIM injection is a sterile‚ clear‚ colorless‚ preservative-free liquid containing filgrastim at a

specific activity of 1.0 ± 0.6 × 108 U/mg (as measured by a cell mitogenesis assay). The product is available in single-dose vials and prefilled syringes. The single-dose vials contain either 300 mcg/mL or 480 mcg/1.6 mL of filgrastim. The single-dose prefilled syringes contain either 300 mcg/0.5 mL or

480 mcg/0.8 mL of filgrastim.

Mechanism of Action

Colony-stimulating factors are glycoproteins which act on hematopoietic cells by binding to specific cell surface receptors and stimulating proliferation‚ differentiation commitment‚ and some end-cell functional activation. Endogenous G-CSF is a lineage-specific colony-stimulating factor that is produced by monocytes‚ fibroblasts, and endothelial cells. G-CSF regulates the production of neutrophils within the bone marrow and affects neutrophil progenitor proliferation‚ differentiation, and selected end-cell functions (including enhanced phagocytic ability‚ priming of the cellular metabolism associated with respiratory burst‚ antibody-dependent killing, and the increased expression of some cell surface antigens). G-CSF is not species-specific and has been shown to have minimal direct in vivo

or in vitro effects on the production or activity of hematopoietic cell types other than the neutrophil lineage.

Pharmacodynamics

In phase 1 studies involving 96 patients with various nonmyeloid malignancies‚ FILGRASTIM

administration resulted in a dose-dependent increase in circulating neutrophil counts over the dose range of 1 to 70 mcg/kg/day. This increase in neutrophil counts was observed whether FILGRASTIM was administered intravenous (1 to 70 mcg/kg twice daily) ‚ subcutaneous (1 to 3 mcg/kg once

daily) ‚ or by continuous subcutaneous infusion (3 to 11 mcg/kg/day). With discontinuation of FILGRASTIM therapy‚ neutrophil counts returned to baseline in most cases within 4 days. Isolated neutrophils displayed normal phagocytic (measured by zymosan-stimulated chemoluminescence) and chemotactic (measured by migration under agarose using N-formyl-methionyl-leucyl-phenylalanine [fMLP] as the chemotaxin) activity in vitro.

The absolute monocyte count was reported to increase in a dose-dependent manner in most patients

receiving FILGRASTIM; however‚ the percentage of monocytes in the differential count remained within the normal range. Absolute counts of both eosinophils and basophils did not change and were within the normal range following administration of FILGRASTIM. Increases in lymphocyte counts following FILGRASTIM administration have been reported in some normal subjects and patients with cancer. White blood cell (WBC) differentials obtained during clinical trials have demonstrated a shift towards earlier granulocyte progenitor cells (left shift)‚ including the appearance of promyelocytes and myeloblasts‚

usually during neutrophil recovery following the chemotherapy

-induced nadir. In addition‚ Dohle bodies‚ increased granulocyte granulation‚ and hypersegmented neutrophils have been observed. Such changes were transient and were not associated with clinical sequelae, nor were they necessarily associated with infection.

[Name]

Generic Name: Filgrastim

Trade Name: JILIFEN

Chemical Name: Human Granulocyte-Colony Stimulating Factor (hG-CSF) Injection

The first human granulocyte stimulating factor in China; Approved by German GMP international certification.

The only one hG-CSF that has been validated by clinical trial phase III. The quality of recombinant protein reached the standard of EP and USP.

Dosage: Injection

Specification:

Ampoule: 50μg(0.2 ml: 4×106IU)，75μg(0.3ml: 6×106IU)，100μg(0.4 ml: 8×106IU), 150μg(0.6 ml: 1.2×107IU), 200μg(0.8 ml: 1.6×107IU), 300μg(1.2ml: 2.4×107IU), 450μg(1.8ml: 3.6×107IU)

Pre-filled syringe: 75μg(0.25ml: 6×106IU), 150μg(0.5ml: 1.2×107IU), 300μg(0.5ml: 2.4×107IU)

[Indication]

1. To enhance neutrophil counts after bone marrow transplantation;

2. Neutropenia induced by anti-cancer chemotherapy;

3. Neutropenia accompanied with Myelodysplastic Syndrome;

4. Neutropenia accompanied with Aplastic Anemia;

5. Congenital or idiopathic neutropenia.

Hangzhou Jiuyuan is a top-biotech joint venture specializing in the research, development, manufacture, and marketing of pharmaceuticals based on gene engineering and biochemical technology since 1993. It has gene engineering workshops, injection workshops, pharmaceutical API workshops, and other sections including the quality management department, warehouse, engineering department, etc., all of which are built according to GMP requirements. Jiuyuan is equipped with advanced production and analysis instruments like chromatography systems, HPLC, and capillary electrophoresis. We offer high-quality products and comprehensive sales services, please contact us.

Marketing Network

Focus on the enterprise purpose of "Take gene engineering as orientation, Render service to human health", the company adheres to serving the Chinese market as the main body and supporting some foreign markets as the auxiliary. Jiuyuan Marketing cultivates a professional, dedicated, and enterprising pharmaceutical service team establishes a stable, credible, and efficient pharmaceutical service network, and focuses on timely delivery of high-quality pharmaceutical products which are the crystallization of scientific research, quality control, and production, to the patients in urgent need, and efficient operation for safe, effective and economic use.

We have been pursuing to improve professional pharmaceutical service skills, expand the radiation capacity of the pharmaceutical service network, and it is our constant pursuit to make Jiuyuan

Pharmaceutical products and medical devices to serve human health.

The marketing network spreads over the country to more than 30 provinces and cities.

The industrial map continues to extend, and the company’s products are exported to Asia, South America, Europe, Africa, and many other countries.

Company Honor

National New High-tech Enterprise

Key New High-tech Enterprise of National Torch Plan

National superior enterprise of intellectual property

Provincial New High-tech Research & Development Center

Zhejiang Provincial Enterprise Technology Center

Zhejiang Famous Trademark

Zhejiang Jiuyuan Gene Engineering Biopharmaceutical Research Institute

Zhejiang province per mu benefit leading enterprises

Gene-engineering New Drug R&D Technology and Service Sub-platform

Provincial Post-doctoral Scientific Research Working Center

Excellent industrial products in Zhejiang Province

Hangzhou Academician Expert Working Center

Hangzhou Top Ten New High-tech Enterprise

Zhejiang Green Enterprise

FAQ

Q: Which certificate do you have?

A: GMP, EUGMP and ISO14001.

Q: Do you have the test and audit service?

A: Yes, we can assist to get the designated test report for product and the designated factory audit report.

Q: What's is your shipping service?

A: We can provide services for vessel booking, goods consolidation, customs declaration, shipping documents preparation and delivery bulk at the shipping port.

Why choose us?

• At our factory, we understand the importance of timeliness, and we strive to deliver quality Oncology Injection products on time, every time.
• Take quality as life and take customers as the center.
• If you're looking to purchase Oncology Injection products in bulk, we can provide you with the best prices and deals.
• Today, our professional team has been able to provide the market' s most complete multi-purpose and mission-specific RhG-CSF Injection(Filgrastim) (Recombinant Human Granulocyte Colony-Stimulating Factor) – A Drug To Increase White Blood Cell Count, CAS No.: 121181-53-1.
• With our state-of-the-art facilities and processes, we can provide innovative Oncology Injection products that meet our clients' unique needs.
• Excellent quality, competitive prices, prompt delivery and dependable service are guaranteed Kindly let us know your quantity requirement under each size category so that we can inform you accordingly.
• Our Chinese factory utilizes innovative production techniques to create Oncology Injection products that meet the industry's highest standards.
• With our exquisite technology, high quality products, thorough technical services and supporting marketing network, we meet the needs of our customers in all aspects.
• Our Chinese factory is well-equipped to cater to small and large orders of Oncology Injection products with fast turnaround times.
• The company will be determined to provide more quality services for the society and customers, continuously enhance the core competitiveness, brand value and sustainable development ability of the Group, reshape the image of a leading enterprise and make new and greater contributions to the development of the economy and society!

Hot Tags: rhg-csf injection(filgrastim) (recombinant human granulocyte colony-stimulating factor) – a drug to increase white blood cell count, cas no.: 121181-53-1, China rhg-csf injection(filgrastim) (recombinant human granulocyte colony-stimulating factor) – a drug to increase white blood cell count, cas no.: 121181-53-1 manufacturers, suppliers, factory, oncology treatment injection, tumor injection, immunotherapy pharmaceutical injection, anti cancer manufacturer injection, cancer order injection, anti cancer distribution injection